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Abstract
Background: Parkinson’s disease (PD) is characterized by the loss of midbrain dopaminergic neurons (DAn).
Previously, we described the presence of DNA hyper- and hypo-methylation alterations in induced pluripotent
stem cells (iPSC)-derived DAn from PD patients using the Illumina 450K array which prominently covers gene
regulatory regions.
Methods: To expand and contextualize previous findings, we performed the first whole-genome DNA bisulfite
sequencing (WGBS) using iPSC-derived DAn from representative PD subjects: one sporadic PD (sPD) patient,
one monogenic LRRK2-associated PD patient (L2PD), and one control.
Results: At the whole-genome level, we detected global DNA hyper-methylation in the PD which was similarly spread
across the genome in both sPD and L2PD and mostly affected intergenic regions.
Conclusion: This study implements previous epigenetic knowledge in PD at a whole genome level providing the first
comprehensive and unbiased CpG DNA methylation data using iPSC-derived DAn from PD patients. Our results indicate
that DAn from monogenic or sporadic PD exhibit global DNA hyper-methylation changes. Findings from this exploratory
study are to be validated in further studies analyzing other PD cell models and patient tissues.
Keywords: Parkinson disease (PD), iPSC-derived DAn, DNA methylation, Whole-genome bisulfite sequencing (WGBS),
DMCpGs, Differentially methylated CpGs
Background
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by motor disabilities due to loss of dopa-
minergic neurons (DAn) in the substantia nigra pars
compacta (SNpc) [1]. Mutations in leucine-rich repeat
kinase 2 (LRRK2) cause monogenic LRRK2-associated
PD (L2PD) and are the most frequent cause of disease
[2]. The LRRK2 p.G2019S variant explains up to 6%
familial and 3% sporadic PD (sPD) cases in Europeans
[3], but the penetrance is limited [4] suggesting add-
itional factors modifying its expressivity [5]. In this con-
text, epigenetic alterations including DNA methylation
changes at CpG sites play a role in neurodegenerative
diseases including Alzheimer’s disease [6, 7]. In PD,
DNA methylation changes were reported in postmortem
brain [7, 8] and blood [9]. An emerging approach for
epigenetic investigation of PD involves the use of iPSC-
derived dopaminergic neurons (DAn) from PD patients.
We recently described aberrant DNA methylation pro-
files in iPSC-derived DAn from 4 L2PD and 6 sPD
patients (total 10 PD vs. 4 controls) [10] which preceded
long-term PD phenotypes in PD DAn [11]. In that study,
we used the Illumina 450K genome-wide methylation
array which interrogates 450,000 CpG in 99% of RefSeq
genes but yet representing only 0.02% of the total CpGs
in the human genome. To expand and contextualize
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previous findings here, we selected the samples with the
highest epigenetic differences between PD and controls
from the previous study which were representative of
different PD states (1 L2PD, 1 sPD, and 1 control) and
performed a whole-genome DNA bisulfite sequencing
(WGBS) analysis. Our study provides the first DNA
methylation fingerprint of monogenic and sporadic PD
using the DAn cells targeted by disease and genuine to
PD live patients [12]. The comprehensive and non-
biased DNA methylation data generated in this study is
informative for the clinic and for designing future epi-
genetic research strategies in PD.
Methods
Subjects
The Local Ethics Committee at the Hospital Clínic de
Barcelona and the Commission on Guarantees for Dona-
tion and Use of Human Tissues and Cells (ISCIII)
approved the study. Subjects were diagnosed and
recruited at the Hospital Clínic de Barcelona after writ-
ten informed consent [10, 11]. We used 30 days iPSC-
derived DAn generated upon reprogramming of skin
fibroblasts into iPSC and differentiation into DAn. De-
tailed protocol [13] and DAn cell line characterization of
study subjects are described previously [10, 11]. Based
on array findings in the 14 subjects of study [10], we
selected for WGBS analysis one representative subject
per condition including 1 L2PD male patient (44 years
old), 1 sPD female patient (51 years old), and 1 female
control (66 years old) (Additional file 1: Table S1).
Whole-genome bisulfite sequencing and library
construction
A total of 2 μg of genomic DNA was spiked with
unmethylated bacteriophage λ DNA (5 ng of λ DNA per
microgram of genomic DNA; Promega) and methylated
T7 phage DNA (5 ng of T7 DNA per microgram of
genomic DNA). DNA was shared by sonication to 50–
500 bp using a LE220 Focused-ultrasonicator (Covaris).
Fragments of 150–300 bp were size-selected using
AMPure XP beads (Agencourt Bioscience). Genomic
DNA libraries were constructed using the Illumina Tru-
Seq Sample Preparation kit following Illumina’s protocol.
After adaptor ligation, DNA was treated with sodium
bisulfite using the EpiTect Bisulfite Kit (Qiagen), follow-
ing the manufacturer’s instructions. Two rounds of
bisulfite conversion were performed to ensure conver-
sion rates above 99%. Enrichment for adaptor-ligated
DNA was done through seven PCR cycles using the
PfuTurboCx Hotstart DNA polymerase (Stratagene).
Library quality was monitored using the Agilent 2100
Bioanalyzer, and concentrations were estimated by
KAPA Library Quantification Kit Illumina® Platforms
(Kapa Biosystems). Paired-end DNA sequencing (2 ×
101 bp) of converted libraries was performed using the
HiSeq2000 (Illumina) following the manufacturer’s
protocol with HiSeq Control Software (HCS-1.5.15.1).
Average sequencing depth was similar and around 30 for
all subjects (27 for L2PD, 32 for sPD, and 31 for the con-
trol). Images analysis, base calling, and quality scoring of
runs were processed using the software Real Time Ana-
lysis (RTA-1.13.48) followed by generation of FASTQ
sequence files. Sequencing data were deposited in the
European Genome-phenome Archive (EGA) at the
Centre for Genomic Regulation (CRG) under accession
Nr. EGAD00001003922.
WGBS data processing and identification of differentially
methylated CpGs
Short read alignment and methylation estimation were
perform using the gemBS analysis pipeline [14]. Single
CpG quantitative methylation values were calculated as
the ratio of unconverted reads to the sum of uncon-
verted and converted reads. We used the GRCh38/hg38
genome version as reference. CpG sites from each
sample were filtered based on a genotype calling quality
threshold (minimum PHREAD-scaled genotype score of
20) to eliminate sites that possibly contained SNPs. In
total, 23,796,355 autosomal CpG sites passed the filters
in all three samples, and this set was used for the subse-
quent analyses. DMCpG were identified from the mul-
tiple pairwise comparison of CpG sites from all 3
subjects, selecting sites where the absolute difference in
the methylation estimates was above 0.25 with a p value
below 1 × 10−8. The p value was calculated using the
approach of Raineri et al. [15], which calculates the exact
probability that two methylation probabilities, estimated
from the ratio of non-converted to converted bases,
differ given the number of converted and non-converted
bases in the two samples. In all cases, hyper- and hypo-
methylation were defined relative to the levels in the
control sample. We defined “uniquePD” as all differen-
tially methylated sites detected in L2PD vs. control and
sPD vs. control, but not in L2PD vs. sPD, i.e., DMCpGs
involved in the common PD pathogenic process. Anno-
tation of DMCpGs to gene-related regions [10] and to
functional chromatin states [16] (epidermal keratinocyte
NHEK-E127) data was done as earlier reported. In
addition, to compare methylation levels between WGBS
and the Illumina 450K array, we calculated correlation
coefficients by performing a Spearman correlation
analysis as requested for non-normal bimodal DNA
methylation data.
Biological enrichment analysis
To determine whether genes associated with DMCpGs
in sPD or L2PD were enriched in particular gene ontol-
ogy (GO) terms, we used the Webgestalt software [17]




Fig. 1 DMCpGs detected by whole-genome bisulfite sequencing in iPSC-derived DAn from L2PD, sPD, and control subjects. a Total of hypo-
methylated (light blue) and hyper-methylated (dark blue) DMCpGs and total DMCpGs (grey). Unique PD (Uniq PD) comprises PD-specific DMCpGs
detected in L2PD vs. control and in sPD vs. controls but not in L2PD vs. sPD. b Histogram of absolute frequencies of overall CpG methylation
levels in study subjects. c Circus plot of whole-genome DNA methylation changes in study subjects. The outer circle displays an ideogram
ordered by chromosome number
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and adjusted the p values by the Benjamini and
Hochberg FDR multiple testing correction [18].
Results
We analyzed the WGBS data from the L2PD, sPD, and
control selected subjects under the standard cutoff of a
methylation difference above 25% and a p < 1 × 10−8. We
observed 1,199,391 differentially methylated CpGs
(DMCpGs) in L2PD vs. control (5.04%) and 1,245,691
DMCpGs in sPD vs. control (5.04%) (Fig. 1a). Per
contrary, we only found 261,459 DMCpGs in L2PD vs.
sPD (1.10%) indicating little difference between PD
cases. Most of the identified DMCpGs, i.e., 729,216
(60%), were common in both PDs. Moreover, the PD-as-
sociated changes consisted of a large DNA hyper-methy-
lation in L2PD and sPD (Fig. 1b, c) (79.8% in L2PD and
84.7% in sPD) whereas hypo-methylation was up to 5-
fold less frequent. In addition, the PD-specific hyper-
methylation was spread throughout the genome.
Altogether, these results indicate a commonly shared
methylation deregulation in monogenic L2PD and sPD
consisting in a global DNA hyper-methylation.
To expand and contextualize previous findings, we
compared the WGBS data from selected subjects
with the 450K data of the entire cohort (n = 4 L2PD,
n = 6 sPD, n = 4 controls) [10]. Over 96% of CpG sites
in the 450K array overlapped with the analyzed set of
CpGs from WGBS. We found an overall high correl-
ation of findings between array and WGBS (Spear-
man’s r = 0.955 for L2PD, 0.951 for sPD, and 0.922
for control) (Additional file 2: Figure S1). Out of the
1261 DMCpGs identified by array in L2PD vs. con-
trols, we found 1116 high-quality CpGs by WGBS
(88.5%) of which 891 (79.8%) were DMCpGs associ-
ated with L2PD (Additional file 1: Table S2). From
the 2512 array DMCpGs in sPD vs. controls, we
detected 2281 CpGs by WGBS (90.8%) of which 1812
(79.9%) were DMCpGs associated with sPD. In
addition to the PD enhancer hyper-methylation
reported earlier at the gene level using the array [10],
at the whole-genome level here we observed a prom-
inent enrichment of hyper-methylated DMCpGs
located at intergenic non-coding regions, in CpG low
regions (“open sea”), and distant from CpG islands
(Fig. 2a, b). Overall, the WGBS data largely over-
lapped but expanded previous array data at the
whole-genome level by showing an intergenic hyper-
methylation which is associated with monogenic
L2PD and sPD.
Finally, we explored the molecular functions regulated
by the PD-associated DMCpGs. To this end, we selected
the 5000 most variable DMCpGs across all samples
identified between PD (L2PD and sPD) and controls
(Additional file 3: Table S3). Of these, 25% DMCpGs
were mapped to intergenic regions whereas the
remaining 75% DMCpGs were annotated to genes. The
biological enrichment analysis of these genes indicated
that the PD-associated methylation largely targeted
genes involved in neural functions (Table 1). These
whole-genome methylation results are in line with previ-
ous epigenetic findings at the gene-related context [10].
Discussion
Here, we report the first WGBS study using iPSC-de-
rived DAn from PD patients. At the whole-genome level,
we found a PD-associated methylation deregulation con-
sisting of a global DNA hyper-methylation common in
monogenic L2PD and sPD. Our findings agree with pre-
vious studies showing that despite subtle differences
[19], L2PD uniquely resembles sPD at the clinical and
A B
Fig. 2 Genomic and functional annotation of DMCpGs in L2PD and sPD. Both CpGs analyzed by WGBS and 450K array data were annotated
using the UCSC Genome Browser database (hg19). Relative distribution of frequencies of unique DMCpGs (i.e., unique and common to L2PD and
sPD) across different gene-related regions (a) and GpG island context (b), showing hypo-methylated DMCpGs (light blue) and hypo-methylated
DMCpGs (dark blue) compared to the background
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neuropathological level [20] where the variant p.G2019S
causes not only L2PD but also sPD without familial seg-
regation. Moreover, despite both PD forms can be initi-
ated by different mechanisms [21], L2PD and sPD were
earlier shown to share common epigenetic, transcrip-
tomic, and microRNA alterations [10, 22]. In addition,
the PD-associated hyper-methylation targeted genes in-
volved in neural functions as reported previously [5], but
in fact, DMCpGs were enriched in intergenic regions.
Although we found a high degree of correlation between
the previous data using the Illumina 450K array and the
present study, this large DNA hyper-methylation was
not previously reported. This was probably due to the
design of the array which mostly focuses on CpGs lo-
cated at gene-related regions. The precise function of
intergenic non-coding regions are only starting to be
uncovered, but these regions could play a role in
pathogenic processes of human disease by affecting
transcription regulatory regions or non-coding tran-
scripts as lncRNAs, miRNAs, siRNAs, piRNAs, and
Table 1 Gene ontology enrichment analysis of genes annotated to the 5000 top-end statistically most significant unique DMCpGs
identified in IPSC-derived DAn from sPD and L2PD patients
Code Biological processes p value FDR
GO:0006928 Movement of cell or subcellular component 6.66E−16 6.06E−12
GO:0040011 Locomotion 5.33E−14 2.42E−10
GO:0022008 Neurogenesis 1.58E−13 4.78E−10
GO:0048646 Anatomical structure formation involved in morphogenesis 2.66E−12 4.38E−09
GO:0048870 Cell motility 2.89E−12 4.38E−09
GO:0051674 Localization of cell 2.89E−12 4.38E−09
GO:0007417 Central nervous system development 4.33E−12 5.49E−09
GO:0009887 Animal organ morphogenesis 5.11E−12 5.49E−09
GO:0030182 Neuron differentiation 5.58E−12 5.49E−09
GO:0048666 Neuron development 6.04E−12 5.49E−09
Code Cellular component p value FDR
GO:0097458 Neuron part 1 < E−17 1 < E−17
GO:0031226 Intrinsic component of plasma membrane 1 < E−17 1 < E−17
GO:0005887 Integral component of plasma membrane 1 < E−17 1 < E−17
GO:0044463 Cell projection part 1 < E−17 1 < E−17
GO:0120038 Plasma membrane-bounded cell projection part 1 < E−17 1 < E−17
GO:0043005 Neuron projection 1 < E−17 1 < E−17
GO:0098590 Plasma membrane region 1 < E−17 1 < E−17
GO:0045202 Synapse 1 < E−17 1 < E−17
GO:0044456 Synapse part 1 < E−17 1 < E−17
GO:0098794 Postsynapse 1 < E−17 1 < E−17
Code Molecular function p value FDR
GO:0008092 Cytoskeletal protein binding 2.34E−07 3.42E−04
GO:0004653 Polypeptide N-acetylgalactosaminyltransferase activity 4.93E−07 3.42E−04
GO:0004714 Transmembrane receptor protein tyrosine kinase activity 7.34E−07 3.42E−04
GO:0001012 RNA polymerase II regulatory region DNA binding 8.79E−07 3.42E−04
GO:0019199 Transmembrane receptor protein kinase activity 9.94E−07 3.42E−04
GO:0000977 RNA polymerase II regulatory region sequence-specific DNA binding 1.25E−06 3.42E−04
GO:0005088 Ras guanyl-nucleotide exchange factor activity 1.28E−06 3.42E−04
GO:0005085 Guanyl-nucleotide exchange factor activity 2.56E−06 6.00E−04
GO:0019904 Protein domain-specific binding 3.30E−06 6.87E−04
GO:0005509 Calcium ion binding 3.85E−06 7.22E−04
Enrichment p values were adjusted by FDR multiple testing correction
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snoRNAs [23], thus potentially contributing to regulating
gene expression of other genes.
In PD animal models, increased global methylation
was proposed as a cause for parkinsonism leading to DA
depletion, hypokinesia, and tremor [24]. Yet global PD
hyper-methylation can be compatible with hypo-methy-
lation at specific promoters as recently shown in PD
blood and cortex [7]. At the gene level, we previously re-
ported a deficit of transcription factors (TF) in PD DAn
relevant to dopaminergic differentiation which was asso-
ciated with PD enhancer hyper-methylation [10]. It is
possible that a deficiency of TFs may mediate genomic
hyper-methylation in specific genomic regions in PD
DAn. One possibility is that the global hyper-methylation
detected in PD at the whole genome level might be related
to functional imbalances in the enzymatic machinery
regulating DNA methylation such as DNA methyltransfer-
ases (DNMTs) or DNA demethylases. In this regard,
DNMTs have been shown to be involved in neural
differentiation [25] and recent studies reported gen-
etic association of DNMTs variants with PD [26, 27]
and their altered expression in PD postmortem brain
[28]. Yet elucidating the biological significance of
the identified PD genomic hyper-methylation and role
of intergenic regions is out of scope of the current
report and requires further investigation.
We previously demonstrated the presence of epigenetic
alterations in iPSC-derived DAn from PD [5]. Here, we
performed a complete characterization of CpG methyla-
tion changes in these cells but the small sample size and
the potential confounder effect of age and gender are a
limitation of this study. In addition, the fact that the re-
programming process from fibroblast to iPSC in itself in-
volves epigenetic modifications could also represent a
confounder effect. Yet, our study provides the first DNA
methylation fingerprint using iPSC-derived DAn from PD
patients by showing a global DNA hyper-methylation
spread across the genome which is similar in monogenic
L2PD and sPD. This comprehensive and unbiased data
may be informative for the clinic to design future epigen-
etic research approaches in PD. Future studies validating
our findings also in PD patient tissues or in PD cell
models and also elucidating the functional role of hyper-
methylation in PD are warranted.
Conclusions
iPSC-derived DAn from PD patients exhibit global
DNA hyper-methylation changes associated with dis-
ease. This hyper-methylation is common to the mono-
genic L2PD and the sporadic forms of disease. Our
study highlights the importance of performing WGBS
as to implement array-based studies to provide an ac-
curate and comprehensive methylation picture of the
PD epigenome.
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Additional file 1: Table S1. Clinic demographic features of study subjects
and iPSC-derived DAn cell lines characterized by whole-genome bisulfite
sequencing (WGBS). Keynote: (a) Initial symptom (T, tremor; B, bradykinesia).
(b) Ratio of neurons/total cells as estimated by immunofluorescence as the
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cells. N/A, not assessed. Table S2. Number of CpGs detected as differentially
methylated CpGs (DMCs) using the Infinium Human Methylation 450K Bead
Chip Kit using iPSC-derived DAn from 6 sPD, 4 L2PD, and 4 healthy controls
in the previous study (Fernandez-Santiago et al., 2015). Of these, number and
percentage of CpGs genotyped, and detected as DMCs by whole genome
bisulfite sequencing (WGBS) at minimum quality 30 read coverage using
representative samples using iPSC-derived DAn from one representative
sample per group (1 L2PD, 1 sPD, and 1 healthy control). (DOCX 16 kb)
Additional file 2: Figure S1. CpGs methylation plots and Spearman’s
correlation coefficients for pairwise comparisons between WGBS and
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Additional file 3: Table S3. List of the top 5000 DMCs in L2PD, sPD, and
uniquePD. (XLSX 2247 kb)
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